Antibodies

16 June 2011

Seattle Genetics Announces FDA Advisory Committee to Review Brentuximab Vedotin for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Systemic ALCL

16 June 2011

FDA approves Nulojix for kidney transplant patients

15 June 2011

ImmunoGen, Inc. Earns Milestone with BAY 94-9343 IND Submission

15 June 2011

Peregrine Reports Promising 12.4 Month Overall Survival Data From Phase II Trial in Non-Small Cell Lung Cancer

13 June 2011

Merck and Hanwha Chemical Corporation Establish Global Strategic Collaboration to Develop and Commercialize Biosimilar Candidate

13 June 2011

Researchers Present Final Data from Phase 2 Studies of Soliris (eculizumab) in Patients with aHUS

10 June 2011

Symphogen Presents Preliminary Results from Phase 2 Clinical Trial with Rozrolimupab at the Annual European Hematology Association

10 June 2011

Millennium and Seattle Genetics Present Clinical Data on ADCETRIS (Brentuximab Vedotin) in Systemic ALCL at EHA Annual Meeting

10 June 2011

Study Demonstrates Micromet’s Blinatumomab Produces High Single-Agent Activity in Patients with Relapsed Acute Lymphoblastic Leukemia

9 June 2011

Seattle Genetics and Agensys, an Affiliate of Astellas, Announce Co-Development of Second Antibody-Drug Conjugate (ADC) Under Existing Collaboration

9 June 2011

XOMA Announces Phase 2a Six-Month Top Line Trial Results Support Safety and Biological Activity

7 June 2011

Quest PharmaTech Provides Oregovomab Chemo Immunotherapy Clinical Trial and other Corporate Updates

7 June 2011

Immunomedics Reports Final Survival Data With Yttrium-90-Labeled Clivatuzumab Tetraxetan and Low-Dose Gemcitabine in Advanced Pancreatic Cancer

7 June 2011

VEGF Trap-Eye Submitted for EU Marketing Authorization for Treatment of Wet Age-Related Macular Degeneration

7 June 2011

Emergent BioSolutions Acquires Late-Stage Monoclonal Antibody Cancer Therapy from TenX BioPharma

6 June 2011

Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer

6 June 2011

Astellas Announces New Study Results Showing Increased Survival Rate for Metastatic Pancreatic Cancer

6 June 2011

ZALTRAP (aflibercept) Significantly Improved Survival in Previously Treated Metastatic Colorectal Cancer Patients

6 June 2011

Symphogen Presents Results from the First Clinical Trial with Sym004 at ASCO

6 June 2011

Seattle Genetics Presents SGN-75 Clinical Data at ASCO Annual Meeting

6 June 2011

Immunomedics Reports First Clinical Results of New Antibody-Directed Radiation Therapy for Colorectal Cancer

6 June 2011

Oxford BioMedica Announces 5T4 Antibody Research Collaboration with ImaginAb

5 June 2011

ImmunoGen, Inc. Announces Positive Clinical Data Presented on IMGN901 in the Treatment of Multiple Myeloma

5 June 2011

Genentech Announces Data to Show Avastin-Based Regimen Halved the Risk of Disease Getting Worse in Women with Recurrent Ovarian Cancer

5 June 2011

Second Phase 3 Study of YERVOY (ipilimumab) in Metastatic Melanoma Meets Primary Endpoint of Overall Survival

3 June 2011

Peregrine Presents Promising Phase II Survival Data in Recurrent GBM With Single Treatment of Cotara at ASCO Annual Meeting

2 June 2011

AVEO’s Ficlatuzumab in Combination with Gefinitib Well Tolerated in Patients with Non-Small Cell Lung Cancer; Phase 1b Data Presented at ASCO

2 June 2011

Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement to Conduct Combination Studies with YERVOY (ipilimumab) and Vemurafenib

2 June 2011

Morphotek, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma

2 June 2011

ImmunoCellular Therapeutics and BioWa Announce License for the Research and Development of Therapeutic Antibodies in Cancer

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2020 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

PD-1 Agonists Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

Report Package: Claudin 18.2-Targeted Immunotherapeutics

c-Met-Targeted Antibody Therapy Pipeline Review

Targeted Protein Degradation by Proteasomal, Lysosomal & Autophagy Pathways 2022: an industry landscape analysis of stakeholders, technologies, pipeline, partnering and financing

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Aflibercept (Eylea) Biosimilars Pipeline Review

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review